SAN FRANCISCO and SUZHOU, China, May 18, 2026
Innovent Biologics presented new clinical and preclinical data from its next-generation autoimmune and ophthalmology pipeline at the 2026 American Thoracic Society (ATS) International Conference and the 2026 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. The company showcased results for three investigational bispecific antibodies — IBI3002, IBI3038, and IBI3031 — targeting inflammatory, fibrotic, and ophthalmologic diseases with significant unmet medical need. The presentations highlighted Innovent’s strategy to advance first-in-class dual-target biologics designed to improve efficacy beyond existing standard-of-care therapies in asthma, fibrosis-related autoimmune diseases, and thyroid eye disease (TED).
IBI3002 Shows Promising Early Clinical Activity in Asthma
One of the key highlights from ATS 2026 was the Phase Ib study of IBI3002, a first-in-class IL-4Rα/TSLP bispecific antibody developed for asthma and other type 2 inflammatory diseases. The randomized, double-blind, placebo-controlled single-dose trial enrolled patients with mild-to-moderate asthma and demonstrated encouraging safety, tolerability, and pharmacodynamic activity.
According to Innovent, IBI3002 simultaneously blocks IL-4Rα and thymic stromal lymphopoietin (TSLP), targeting two major inflammatory pathways involved in airway inflammation. Clinical data showed improvements in lung function and inflammatory biomarkers compared with placebo. Patients treated with IBI3002 achieved stronger improvements in pre-bronchodilator forced expiratory volume (FEV1) and reductions in fractional exhaled nitric oxide (FeNO), eosinophils, immunoglobulin E (IgE), and TARC levels. Preclinical findings also showed superior reduction of airway inflammation compared with currently marketed biologics including dupilumab and tezepelumab.
Innovent stated that the dual-blockade mechanism could provide a more comprehensive therapeutic strategy for patients with heterogeneous asthma who continue to experience inadequate disease control with current therapies. The company plans to further develop IBI3002 for both asthma and atopic dermatitis.
Innovent Advances Fibrosis and Thyroid Eye Disease Programs
Advertisement
At ATS 2026, Innovent also presented preclinical results for IBI3038, a first-in-class IGF-1R/IL-6 bispecific antibody being developed for fibrosis-related autoimmune diseases including systemic sclerosis-associated interstitial lung disease (SS-ILD). Preclinical studies demonstrated that IBI3038 potently inhibited both fibrotic and inflammatory signaling pathways, outperforming comparator therapies in several experimental models.
The investigational therapy significantly reduced fibroblast proliferation, hyaluronic acid production, collagen deposition, and lung fibrosis progression in preclinical studies. Innovent reported that dual inhibition of IGF-1R and IL-6 produced stronger anti-fibrotic activity than targeting either pathway alone. The company believes this approach may provide a differentiated treatment option for patients with severe fibrotic autoimmune diseases, where effective therapies remain limited.
Meanwhile, at ARVO 2026, Innovent presented data for IBI3031, a novel IGF-1R/TSHR bispecific antibody for thyroid eye disease (TED). The therapy demonstrated promising preclinical activity by suppressing orbital fibroblast proliferation, hyaluronic acid secretion, and inflammatory signaling associated with TED progression. In animal models, IBI3031 reduced expansion of orbital fat and muscle tissue linked to disease severity.
The company also highlighted favorable pharmacokinetic properties in non-human primates, suggesting the potential for extended dosing intervals and improved patient convenience compared with existing therapies. Innovent expects both IBI3038 and IBI3031 to enter clinical development during 2026 as it continues expanding its autoimmune and ophthalmology pipeline.
Bispecific Antibody Strategy Expands Innovent’s Pipeline
Innovent executives emphasized that the ATS and ARVO presentations reinforce the company’s growing capabilities in bispecific antibody engineering and mechanism-driven drug development. By targeting multiple disease-driving pathways simultaneously, Innovent aims to improve treatment outcomes across complex chronic diseases involving inflammation, fibrosis, and immune dysregulation.
The company currently markets multiple commercial products and maintains a broad pipeline spanning oncology, autoimmune diseases, cardiovascular conditions, and ophthalmology. Innovent stated that continued investment in next-generation biologics and global partnerships remains central to its strategy of delivering differentiated therapies for diseases with limited treatment options.
Source: Innovent Biologics press release
